EUSARNAD · Joint European and South African Research Network in Anxiety Disorders
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2011-10-01 → 2015-09-30
- Финансиране от ЕС
- 289 800 €
- Участници
- 13
- Схема
- MC-IRSES
Линиите свързват координатора с партньорите.
Накратко на български
Тревожните разстройства се изследват чрез генетика, невронаука и психология, за да се разберат причините за появата им. Това помага за разработването на по-подходящи методи за лечение, съобразени с индивидуалните особености на всеки пациент.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Joint European and South African Research Network in Anxiety Disorders
Anxiety disorders are common, distressing and impairing conditions - but many people remain unrecognized and even in those who are diagnosed the standard of clinical care received is usually less than optimal. Advances in genetics, neuroscience, pharmacology and psychology research have all deepened our understanding of the causes and treatment of anxiety symptoms and anxiety disorders, however on an individual basis it is difficult to predict who will become troubled by symptoms, and it is hard to make personalised treatment decisions designed to improve clinical outcomes. The European and South African Research Network in Anxiety Disorders (‘EUSARNAD’) programme aimed to establish an international collaborative network for refining research methodologies and developing and evaluating innovative treatments for patients with anxiety disorders. EUSARNAD thereby contributed to initiatives both to enhance understanding of the causes of anxiety disorders and to target the delivery of improved treatments. During the four-year programme, individual exchange researchers were affiliated to research active teams in the participating institutions, and gained access to knowledge and expertise at each participating centre. EUSARNAD included 14 centres of excellence for research into anxiety disorders and builds on the Anxiety Disorders Research Network (ADRN), itself supported by the European College of Neuropsychopharmacology Network Initiative (Table 1). EUSARNAD strengthens and extends current collaborative work with the University of Cape Town. South African early stage researchers gained experience of certain research methodologies in European centres, and European early stage researchers developed a greater understanding of the origin of anxiety disorders and problems in their management in an emerging country. The EUSARNAD thereby enhanced the relevance of translational research in developed and developing societies. EUSARNAD was funded by the European Commission, through the Marie Curie Actions (People) International Research Staff Exchange Scheme awarded in August 2011 (project number PIRSES-GA-2010-269213). The EU contribution was determined by the number of eligible person months; and those funds supported travel and subsistence costs, networking activities, management costs and overheads related to implementing the exchange. (Table 2 lists the 11 Work Packages.) In the 48 months of the programme a total of 27 secondments took place between European centres and University of Cape Town. These exchanges have so far resulted in 24 scientific publications/ manuscripts, including joint publications between the researchers, 15 abstracts of scientific posters, and in several collaborations between early stage researchers. Programme exchangees also benefited from training in the host institutions and through conferences they attended, including the British Association for Psychopharmacology Conference (BAP, July 2012), ECNP Congress in Vienna (October, 2012), International Anxiety Disorder Symposium (IADS) conference in Cape Town (February, 2013), BAP Conference (July 2013), Collegium Internationale Neuro-Psychopharmacologicum (CINP) Conference in Cape Town (March 2015), and British Association for Psychopharmacology (BAP) Masterclass in Psychopharmacology in London (April 2015). During the IADS conference the first EUSARNAD Colloquium was held, where researchers who had participated or were currently participating in the programme had a chance share their experience and provide feedback about the project. The EUSARNAD Colloquium at the IADS was chaired by and independent expert in anxiety disorders Professor Christer Allgulander of the Karolinska Institutet, Stockholm and was judged to be a great success by the attending exchangees and the participating centre leads – Professors Baldwin (Southampton), Bandelow (Goettingen), Fineberg (Hertfordshire) and Stein (Cape Town). The second EUSARNAD Colloquium took place on March 9th 2015 in Cape Town during the CINP conference. Nine EUSARNAD early stage researchers delivered a presentation on their achievements following secondments. The meeting was chaired by Prof David Baldwin and co-chaired by Prof Dan Stein.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The overall aim of our proposal is to build on the strengths of an existing European network for research into causes and maintaining factors in anxiety disorders and to extend these by establishing firmer research collaboration with the University of Cape Town in South Africa.Through establishing this research exchange, we aim to share knowledge and expertise among participating centres, and ensure a comprehensive translational research approach in anxiety disorders, relevant to the needs of developed and developing societies.The exchange scheme has three broad objectives. First, to develop a collaborative international database for the detailed characterisation of large samples of patients, across the range of anxiety disorders. Second, to provide exchange researchers with a range of complementary training opportunities, gaining experience in innovative investigations in anxiety disorders. These opportunities include characterisation of differing endophenotypes across diagnoses; using neuroimaging, genetic polymorphism and other techniques to bridge the gap between preclinical and clinical studies; and identifying predictors of clinical outcome and treatment response using dimensional and other approaches. Third, to establish a firm platform to support subsequent pragmatic randomised effectiveness trials in patients who have not responded to previous treatment interventions.The value of the scheme is in its capacity to facilitate access to additional and larger clinical populations, to include centres of research excellence across many countries, and to share the knowledge and expertise of leading researchers with long-standing and wide-ranging interests in anxiety disorders. Furthermore, the training opportunities within the scheme would increase the knowledge and skills of the ‘next generation’ of anxiety disorder researchers and thereby contribute to efforts to meet the challenges imposed by these common, burdensome and costly medical conditions.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITY OF SOUTHAMPTON · SOUTHAMPTONКоординаторОбединеното кралство
- ACADEMISCH ZIEKENHUIS GRONINGEN · GroningenНидерландия
- ACADEMISCH ZIEKENHUIS LEIDEN · LeidenНидерландия
- GOETEBORGS UNIVERSITET · GoeteborgШвеция
- MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER · Ramat GanИзраел
- TARTU ULIKOOL · TartuЕстония
- THE UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION · HatfieldОбединеното кралство
- UNIVERSIDAD DE CANTABRIA · SANTANDERИспания
- UNIVERSITA DEGLI STUDI DI MILANO · MilanoИталия
- UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT · WURZBURGГермания
- UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS · GoettingenГермания
- UNIVERSITY OF BRISTOL · BRISTOLОбединеното кралство
- UPPSALA UNIVERSITET · UppsalaШвеция
Връзки
- Виж в CORDIS
- http://blog.soton.ac.uk/eusarnad/
- https://web.archive.org/web/20160324162404/http://blog.soton.ac.uk/eusarnad/
Данни: CORDIS, © Европейски съюз
